Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.

E. V. Vinnitskaya, S. R. Abdulkhakov, D. T. Abdurakhmanov, R. B. Alikhanov, I. G. Bakulin, E. A. Belousova, A. O. Bueverov, E. Z. Burnevitch, M. G. Efanov, E. Yu Eremina, Ignatova, L. Yu Ilchenko, G. G. Karmazanovsky, O. V. Knyazev, Yu V. Kulezneva, T. N. Lopatkina, T. P. Nekrasova, V. V. Pavlenko, S. D. Podymova, K. L. RaichelsonA. R. Reisis, R. G. Sayfutdinov, E. V. Skazyvaeva, S. G. Khomeriki, T. Yu Haimenova, Yu G. Sandler

Research output

Abstract

The article is published based on the results of the Russian Consensus on the diagnosis and treatment of primary sclerosing cholangitis (PSC), discussed at the 44 th annual Scientific Session of the CNIIG "Personalized Medicine in the Era of Standards" (March 1, 2018). The aim of the review is to highlight the current issues of classification of diagnosis and treatment of patients with PSC, which causes the greatest interest of specialists. The urgency of the problem is determined by the multivariate nature of the clinical manifestations, by often asymptomatic flow, severe prognosis, complexity of diagnosis and insufficient study of PSC, the natural course of which in some cases can be considered as a function with many variables in terms of the nature and speed of progression with numerous possible clinical outcomes. In addition to progression to portal hypertension, cirrhosis and its complications, PSC can be accompanied by clinical manifestations of obstructive jaundice, bacterial cholangitis, cholangiocarcinoma and colorectal cancer. Magnetic resonance cholangiography is the main method of radial diagnostics of PSC, which allows to obtain an image of bile ducts in an un-invasive way. The use of liver biopsy is best justified when there is a suspicion of small-diameter PSC, autoimmune cross-syndrome PSC-AIG, IgG4-sclerosing cholangitis. Currently, a drug registered to treat primary sclerosing cholangitis which can significantly change the course and prognosis of the disease does not exist. There is no unified view on the effectiveness and usefulness of ursodeoxycholic acid and its dosage in PSC. Early diagnosis and determination of the phenotype of PSC is of clinical importance. It allows to determine the tactics of treatment, detection and prevention of complications.

Original languageRussian
Pages (from-to)9-15
Number of pages7
JournalТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)
Volume91
Issue number2
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Autoimmune Hepatitis
Sclerosing Cholangitis
Moscow
Therapeutics
Ursodeoxycholic Acid
Precision Medicine
Cholangitis
Cholangiocarcinoma
Obstructive Jaundice
Cholangiography
Portal Hypertension
Bile Ducts
Early Diagnosis
Colorectal Neoplasms
Fibrosis
Magnetic Resonance Spectroscopy
Immunoglobulin G

Scopus subject areas

  • Medicine(all)

Cite this

Vinnitskaya, E. V. ; Abdulkhakov, S. R. ; Abdurakhmanov, D. T. ; Alikhanov, R. B. ; Bakulin, I. G. ; Belousova, E. A. ; Bueverov, A. O. ; Burnevitch, E. Z. ; Efanov, M. G. ; Eremina, E. Yu ; Ignatova ; Ilchenko, L. Yu ; Karmazanovsky, G. G. ; Knyazev, O. V. ; Kulezneva, Yu V. ; Lopatkina, T. N. ; Nekrasova, T. P. ; Pavlenko, V. V. ; Podymova, S. D. ; Raichelson, K. L. ; Reisis, A. R. ; Sayfutdinov, R. G. ; Skazyvaeva, E. V. ; Khomeriki, S. G. ; Haimenova, T. Yu ; Sandler, Yu G. / Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г. In: ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV). 2019 ; Vol. 91, No. 2. pp. 9-15.
@article{3704891ad35a4b5f80a80a11fe415a5e,
title = "Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.",
abstract = "The article is published based on the results of the Russian Consensus on the diagnosis and treatment of primary sclerosing cholangitis (PSC), discussed at the 44 th annual Scientific Session of the CNIIG {"}Personalized Medicine in the Era of Standards{"} (March 1, 2018). The aim of the review is to highlight the current issues of classification of diagnosis and treatment of patients with PSC, which causes the greatest interest of specialists. The urgency of the problem is determined by the multivariate nature of the clinical manifestations, by often asymptomatic flow, severe prognosis, complexity of diagnosis and insufficient study of PSC, the natural course of which in some cases can be considered as a function with many variables in terms of the nature and speed of progression with numerous possible clinical outcomes. In addition to progression to portal hypertension, cirrhosis and its complications, PSC can be accompanied by clinical manifestations of obstructive jaundice, bacterial cholangitis, cholangiocarcinoma and colorectal cancer. Magnetic resonance cholangiography is the main method of radial diagnostics of PSC, which allows to obtain an image of bile ducts in an un-invasive way. The use of liver biopsy is best justified when there is a suspicion of small-diameter PSC, autoimmune cross-syndrome PSC-AIG, IgG4-sclerosing cholangitis. Currently, a drug registered to treat primary sclerosing cholangitis which can significantly change the course and prognosis of the disease does not exist. There is no unified view on the effectiveness and usefulness of ursodeoxycholic acid and its dosage in PSC. Early diagnosis and determination of the phenotype of PSC is of clinical importance. It allows to determine the tactics of treatment, detection and prevention of complications.",
keywords = "первичный склерозирующий холангит, фенотипы,биопсия печени, магнитро-резонансная холангиография,урсодезоксихолевая кислота",
author = "Vinnitskaya, {E. V.} and Abdulkhakov, {S. R.} and Abdurakhmanov, {D. T.} and Alikhanov, {R. B.} and Bakulin, {I. G.} and Belousova, {E. A.} and Bueverov, {A. O.} and Burnevitch, {E. Z.} and Efanov, {M. G.} and Eremina, {E. Yu} and Ignatova and Ilchenko, {L. Yu} and Karmazanovsky, {G. G.} and Knyazev, {O. V.} and Kulezneva, {Yu V.} and Lopatkina, {T. N.} and Nekrasova, {T. P.} and Pavlenko, {V. V.} and Podymova, {S. D.} and Raichelson, {K. L.} and Reisis, {A. R.} and Sayfutdinov, {R. G.} and Skazyvaeva, {E. V.} and Khomeriki, {S. G.} and Haimenova, {T. Yu} and Sandler, {Yu G.}",
note = "Винницкая Е.В., Абдулхаков С.Р., Абдурахманов Д.Т. и др. Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.). Терапевтический архив. 2019; 91 (2): 8–15. DOI: 10.26442/00403660.2019.02.000075",
year = "2019",
month = "1",
day = "1",
doi = "10.26442/00403660.2019.02.000075",
language = "русский",
volume = "91",
pages = "9--15",
journal = "ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)",
issn = "0040-3660",
publisher = "Медицина",
number = "2",

}

Vinnitskaya, EV, Abdulkhakov, SR, Abdurakhmanov, DT, Alikhanov, RB, Bakulin, IG, Belousova, EA, Bueverov, AO, Burnevitch, EZ, Efanov, MG, Eremina, EY, Ignatova, Ilchenko, LY, Karmazanovsky, GG, Knyazev, OV, Kulezneva, YV, Lopatkina, TN, Nekrasova, TP, Pavlenko, VV, Podymova, SD, Raichelson, KL, Reisis, AR, Sayfutdinov, RG, Skazyvaeva, EV, Khomeriki, SG, Haimenova, TY & Sandler, YG 2019, 'Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.', ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV), vol. 91, no. 2, pp. 9-15. https://doi.org/10.26442/00403660.2019.02.000075, https://doi.org/10.26442/00403660.2019.02.000075

Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г. / Vinnitskaya, E. V.; Abdulkhakov, S. R.; Abdurakhmanov, D. T.; Alikhanov, R. B.; Bakulin, I. G.; Belousova, E. A.; Bueverov, A. O.; Burnevitch, E. Z.; Efanov, M. G.; Eremina, E. Yu; Ignatova; Ilchenko, L. Yu; Karmazanovsky, G. G.; Knyazev, O. V.; Kulezneva, Yu V.; Lopatkina, T. N.; Nekrasova, T. P.; Pavlenko, V. V.; Podymova, S. D.; Raichelson, K. L.; Reisis, A. R.; Sayfutdinov, R. G.; Skazyvaeva, E. V.; Khomeriki, S. G.; Haimenova, T. Yu; Sandler, Yu G.

In: ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV), Vol. 91, No. 2, 01.01.2019, p. 9-15.

Research output

TY - JOUR

T1 - Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.

AU - Vinnitskaya, E. V.

AU - Abdulkhakov, S. R.

AU - Abdurakhmanov, D. T.

AU - Alikhanov, R. B.

AU - Bakulin, I. G.

AU - Belousova, E. A.

AU - Bueverov, A. O.

AU - Burnevitch, E. Z.

AU - Efanov, M. G.

AU - Eremina, E. Yu

AU - Ignatova,

AU - Ilchenko, L. Yu

AU - Karmazanovsky, G. G.

AU - Knyazev, O. V.

AU - Kulezneva, Yu V.

AU - Lopatkina, T. N.

AU - Nekrasova, T. P.

AU - Pavlenko, V. V.

AU - Podymova, S. D.

AU - Raichelson, K. L.

AU - Reisis, A. R.

AU - Sayfutdinov, R. G.

AU - Skazyvaeva, E. V.

AU - Khomeriki, S. G.

AU - Haimenova, T. Yu

AU - Sandler, Yu G.

N1 - Винницкая Е.В., Абдулхаков С.Р., Абдурахманов Д.Т. и др. Актуальные вопросы диагностики и лечения первичного склерозирующего холангита (по материалам Российского Консенсуса по диагностике и лечению первичного склерозирующего холангита. Москва, 2018 г.). Терапевтический архив. 2019; 91 (2): 8–15. DOI: 10.26442/00403660.2019.02.000075

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The article is published based on the results of the Russian Consensus on the diagnosis and treatment of primary sclerosing cholangitis (PSC), discussed at the 44 th annual Scientific Session of the CNIIG "Personalized Medicine in the Era of Standards" (March 1, 2018). The aim of the review is to highlight the current issues of classification of diagnosis and treatment of patients with PSC, which causes the greatest interest of specialists. The urgency of the problem is determined by the multivariate nature of the clinical manifestations, by often asymptomatic flow, severe prognosis, complexity of diagnosis and insufficient study of PSC, the natural course of which in some cases can be considered as a function with many variables in terms of the nature and speed of progression with numerous possible clinical outcomes. In addition to progression to portal hypertension, cirrhosis and its complications, PSC can be accompanied by clinical manifestations of obstructive jaundice, bacterial cholangitis, cholangiocarcinoma and colorectal cancer. Magnetic resonance cholangiography is the main method of radial diagnostics of PSC, which allows to obtain an image of bile ducts in an un-invasive way. The use of liver biopsy is best justified when there is a suspicion of small-diameter PSC, autoimmune cross-syndrome PSC-AIG, IgG4-sclerosing cholangitis. Currently, a drug registered to treat primary sclerosing cholangitis which can significantly change the course and prognosis of the disease does not exist. There is no unified view on the effectiveness and usefulness of ursodeoxycholic acid and its dosage in PSC. Early diagnosis and determination of the phenotype of PSC is of clinical importance. It allows to determine the tactics of treatment, detection and prevention of complications.

AB - The article is published based on the results of the Russian Consensus on the diagnosis and treatment of primary sclerosing cholangitis (PSC), discussed at the 44 th annual Scientific Session of the CNIIG "Personalized Medicine in the Era of Standards" (March 1, 2018). The aim of the review is to highlight the current issues of classification of diagnosis and treatment of patients with PSC, which causes the greatest interest of specialists. The urgency of the problem is determined by the multivariate nature of the clinical manifestations, by often asymptomatic flow, severe prognosis, complexity of diagnosis and insufficient study of PSC, the natural course of which in some cases can be considered as a function with many variables in terms of the nature and speed of progression with numerous possible clinical outcomes. In addition to progression to portal hypertension, cirrhosis and its complications, PSC can be accompanied by clinical manifestations of obstructive jaundice, bacterial cholangitis, cholangiocarcinoma and colorectal cancer. Magnetic resonance cholangiography is the main method of radial diagnostics of PSC, which allows to obtain an image of bile ducts in an un-invasive way. The use of liver biopsy is best justified when there is a suspicion of small-diameter PSC, autoimmune cross-syndrome PSC-AIG, IgG4-sclerosing cholangitis. Currently, a drug registered to treat primary sclerosing cholangitis which can significantly change the course and prognosis of the disease does not exist. There is no unified view on the effectiveness and usefulness of ursodeoxycholic acid and its dosage in PSC. Early diagnosis and determination of the phenotype of PSC is of clinical importance. It allows to determine the tactics of treatment, detection and prevention of complications.

KW - первичный склерозирующий холангит, фенотипы,биопсия печени, магнитро-резонансная холангиография,урсодезоксихолевая кислота

UR - http://www.scopus.com/inward/record.url?scp=85063649454&partnerID=8YFLogxK

U2 - 10.26442/00403660.2019.02.000075

DO - 10.26442/00403660.2019.02.000075

M3 - статья

AN - SCOPUS:85063649454

VL - 91

SP - 9

EP - 15

JO - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

JF - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

SN - 0040-3660

IS - 2

ER -